Since the early 1990s, numerous cancer Ag have been defined and for a handful of these
there is now some clinical experience, which has made it possible to assess their value as …

The identification of novel tumor-associated antigens, especially those shared among
patients, is urgently needed to improve the efficacy of immunotherapy for multiple myeloma …

Analog peptides represent a promising tool to further optimize peptide-based vaccines in
promoting the expansion of tumor antigen-specific cytotoxic T lymphocytes. Here, we report …

NY-ESO-1 is a cancer/testis antigen expressed in normal adult tissues solely in the testicular
germ cells of normal adults and in various cancers. It induces specific humoral and cellular …

Antigens that are selectively or abundantly expressed in cancer cells have been used for
clinical trials, mostly in patients with advanced disease, and appear to be better vaccines …

Nanoparticles have attracted considerable interest as cancer vaccine delivery vehicles for
inducing sufficient CD8+ T cell-mediated immune responses to overcome the low …

Background The host's immune system develops in equilibrium with both cellular self-
antigens and non-self-antigens derived from microorganisms which enter the body during …

By stimulating human CD8+ T lymphocytes with autologous dendritic cells infected with an
adenovirus encoding MAGE-3, we obtained a cytotoxic T lymphocyte (CTL) clone that …

Presentation of intracellular tumor-associated Ags (TAAs) in the context of HLA class I
molecules offers unique cancer-specific cell surface markers for the identification and …

The specific activation of the immune system to control cancer growth in vivo has been a
long‐standing goal in cancer immunology and medical oncology. The identification of tumor …